Navigation Links
Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
Date:3/16/2009

1, 2008, compared with $5.9 million for the same period in 2007.

Beginning October 21, 2008, Pfizer became responsible for 60 percent of all Dimebon-related development and commercialization costs in the U.S., and 100 percent of such costs outside the U.S. The parties will make quarterly true-up payments as necessary to ensure that each bears its applicable share of costs. For the fourth quarter of 2008, the true-up payment payable to Medivation was $3.5 million. Medivation presents these cost-sharing true-up payments in the applicable expense line of its statement of operations.

Medivation reported a net loss for the quarter ended December 31, 2008, of $7.9 million, or $0.26 per share, compared with a net loss of $9.6 million, or $0.34 per share, for the same period in 2007. For the twelve months ended December 31, 2008, the net loss was $62.5 million, or $2.12 per share, compared with a net loss of $31.7 million, or $1.14 per share, for the same period in 2007.

Cash, cash equivalents and short-term investments at December 31, 2008, totaled $221.4 million, compared with $43.3 million at December 31, 2007.

2009 Financial Outlook

We expect 2009 revenue from our collaboration with Pfizer to be approximately $65 million, representing partial recognition of our $225 million up-front payment received. We do not expect to recognize any Dimebon related milestone payments in 2009. We expect that total operating expenses for 2009, net of cost-sharing payments from Pfizer, will be between $130 and $140 million, which includes non-cash stock-based compensation expense of approximately $10 million.

Conference Call Information

To participate in today's live call beginning at 4:30 p.m. Eastern Time by telephone, please call 877-718-5104 from the U.S. or +1-719-325-4794 internationally. In addition, the live conference call is being webcast and can be access
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
2. Medivation Presents New Data on Dimebons Novel Mechanism of Action
3. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
4. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
5. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
6. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
7. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
8. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
9. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
10. Medivation Announces Participation in Upcoming Conferences
11. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 /PRNewswire/ ... company in the emerging field of regenerative medicine, ... webcast of a presentation to investors on Tuesday, ... p.m. PDT.  The presentation will include an overview ... To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
(Date:7/24/2014)... computers have yet to materialise. Yet, scientists are ... such computers faster. One such approach relies on ... by applying an electric field. A new study ... coupled quantum dots (TQDs) with electrical impulses can ... example, should TQDs be used as quantum information ...
(Date:7/24/2014)... 24, 2014 Research and Markets ... and Proteomics Analytical Instruments Market 2014-2018" report to ... Genomics is the study of the gene ... the structure and functions of proteomes or sets of ... technology. Genomics involves the mapping of genes and DNA ...
(Date:7/24/2014)... July 24, 2014 Three companies from ... in Livestrong’s Big C Competition. Out of 700 competition ... headed to the semi-final round. In this round twenty ... accelerator program, complete with mentoring from thought-leaders and medical ... part of the angelMD commitment to the Livestrong vision ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... Angiotech Pharmaceuticals, Inc. ("Angiotech") (NASDAQ: ANPI , ... meeting of shareholders will take place on June 4, ... Grand Vancouver, 403 Robson Street, Vancouver, BC V6B 6L9. ... of and vote at the meeting will be April ...
... be invested in the first phase of this personalized ... National Functional Genomics Center , funded ... by the U.S. Army Medical Research & ... Telemedicine & Advanced Technology Research Center (TATRC), ...
... SILVER SPRING, Md., April 24 United Therapeutics Corporation ... will release its 2009 first quarter financial results before ... host a half-hour teleconference on Friday, May 1, 2009, ... accessible by dialing 877-718-5092, with international callers dialing 719-325-4795. ...
Cached Biology Technology:NFGC Conducts Multi-Institutional Research Project in Ovarian Cancer 2NFGC Conducts Multi-Institutional Research Project in Ovarian Cancer 3
(Date:7/25/2014)... Boston, MA A study published online in the ... describes a novel approach to preventing cervical cancer based ... cervical cancer after removal of a discrete population of ... from a study that looked at squamocolumnar junction cells, ... canal and have been implicated as the origins of ...
(Date:7/25/2014)... characterized by the existence of numerous isoforms arising ... the protein deeply different characteristics. NRG1 plays an ... development and the different phases occurring after injury ... remyelination and target reinnervation, Researchers at the University ... NRG1 upregulation observed in Schwann cells immediately after ...
(Date:7/25/2014)... use of a molecular testing panel developed at ... correct initial surgery for patients with thyroid nodules ... Pittsburgh Cancer Institute (UPCI), partner with UPMC CancerCenter., ... Center and other diagnostic testing agencies, improved the ... by 30 percent, according to the study published ...
Breaking Biology News(10 mins):Clearing cells to prevent cervical cancer 2Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3
... A major international study with leadership from Massachusetts General ... associated with blood sugar or insulin levels. Two ... associated with glucose levels were also found to increase ... a related study from members of the same research ...
... a team of researchers is releasing data today that it ... the family of parasites that causes a deadly trio of ... nations for centuries. In an article to be published ... , Vanderbilt University scientist Galina Lepesheva and her team are ...
... A breakthrough discovery by scientists at the University of Kentucky ... diseases of the brain, spinal cord and the eye. ... visual science in the UK College of Medicine, found that ... proteins vimentin and glial fibrillary acidic protein (GFAP) ...
Cached Biology News:New gene variants associated with glucose, insulin levels, some with diabetes risk 2Scientists hope to end sleeping sickness by making parasite that causes it self-destruct 2Scientists hope to end sleeping sickness by making parasite that causes it self-destruct 3Kentucky study advances new target for CNS drug development 2
Human Aminopeptidase P1/XPNPEP1 Affinity Purified PAb Protein Family: Aminopeptidases, Metalloproteases...
Template and primers for preparation of internal control spots...
Cross reactivity to St. Louis encephalitis (MSI-7) is determined by ELISA....
...
Biology Products: